Abstract | OBJECTIVE: DESIGN: Open-label, prospective study. SETTING: Tertiary referral hospital. PATIENTS: INTERVENTION:
Octreotide in a 6-month, stepwise incremental dosage. MEASUREMENTS: RESULTS: A 50% decrease occurred in the respiratory disturbance index (baseline compared with 6 months, 39 events/h compared with 19 events/h; P = 0.0002), and a 40% decrease occurred in total apnea time (27.6% of total sleep time compared with 15.1%; P = 0.001). Indices of oxygen desaturation, sleep quality, and subjective sleepiness improved after 6 months of octreotide. A parallel decrease was noted in mean levels of growth hormone (40.0 micrograms/L compared with 9.1 micrograms/L; P = 0.003) and IGF-1 (107 nmol/L compared with 47 nmol/L; P = 0.0001). However, no correlation was noted between the decrease in the total amount of sleep time spent in apnea and the decrease in growth hormone levels (rho = -0.35; P > 0.2). The residual respiratory disturbance index after 6 months of treatment was similar in patients who improved, regardless of whether or not biochemical remission (IGF-1 < 35 nmol/L) occurred. CONCLUSIONS:
|
Authors | R R Grunstein, K K Ho, C E Sullivan |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 121
Issue 7
Pg. 478-83
(Oct 01 1994)
ISSN: 0003-4819 [Print] United States |
PMID | 8067645
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Insulin-Like Growth Factor I
- Growth Hormone
- Octreotide
- Oxygen
|
Topics |
- Acromegaly
(blood, complications, drug therapy)
- Adult
- Aged
- Female
- Growth Hormone
(blood)
- Humans
- Insulin-Like Growth Factor I
(metabolism)
- Male
- Middle Aged
- Octreotide
(therapeutic use)
- Oxygen
(physiology)
- Prospective Studies
- Respiration
(drug effects)
- Sleep Apnea Syndromes
(complications, drug therapy, physiopathology)
|